Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 17Glioblastoma 8Esophageal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Oropharyngeal Neoplasms 7Breast Neoplasms 7Mouth Neoplasms 6Glioma 6Triple Negative Breast Neoplasms 4Lung Neoplasms 4Laryngeal Neoplasms 4Head and Neck Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Sarcoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Neuroblastoma 2Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Medulloblastoma 2Hypopharyngeal Neoplasms 2Ganglioneuroblastoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

atezolizumab 2lipoarabinomannan 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Lamivudine 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Extensive Stage Lung Small Cell Carcinoma × Radiation × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡